Day 1 :
Global Harmonization Initiative (GHI), Austria
Time : 10:15-10:45
Huub Lelieveld is President of the Global Harmonization Initiative and fellow of the International Academy of Food Science and Technology. He editor or co-editor of numerous books, including “Hygiene in food processing”, the “Handbook of hygiene control in the food industry”, “Food preservation by pulsed electric fields”, “Ensuring Global Food Safety: Exploring Global Harmonization”, “Regulating Safety of Traditional and Ethnic Foods”, “Hygienic design of food factories”, ”Food safety management: a practical guide for the food industry” and “High Pressure Processing of Food – Principles, Technology and Applications”. He wrote chapters for many books and encyclopaedia, hundreds of scientific articles and articles for magazines and presented hundreds of papers, globally. He has been awarded doctor honoris causa at the National University of Food Technologies in Kiev, Ukraine and has got several other awards in Europe and the USA.
Regrettably after decades of negotiations between countries and supranational organizations, there are still too many differences that hamper movement of safe food across borders and hamper innovations and it does not look like the differences will disappear soon. Therefore, where possible, serious scientists should continue to work together to provide scientifically correct evidence that may be used as tools by stakeholders to try influence negotiations and to try convince local authorities that harmonization is in the interest of everybody. To make it work in practice requires that the scientific evidence is understood by those who need to know and that means most people, at all levels. Not only large companies are affected by unjustified differences in regulations, but also small companies and street vendors and ultimately all consumers, who in many countries have a democratic vote and thus are influential. In turn this makes it necessary that the science is translated in a language that the those who need to know understand. The Global Harmonization Initiative therefore not only tries to find consensus on scientific issues, but also seeks means to make the findings understood by everybody, requiring simplification, but without losing the true scientific facts, and translation into local languages. Then having the results published in, scientific journals, popular scientific magazines, newspapers and magazines aimed at the general public. Another crucial aspect is that those who do the negotiations understand what they are talking about, because expressions used in regulations and during negotiations tend to have – often vastly - different meanings in different countries or regions.
CytoSolve Inc, USA
Time : 11:00-11:30
V.A. Shiva Ayyadurai, the inventor of email and polymath, holds four degrees from MIT and is a world-renowned systems scientist. He is a Fulbright Scholar, Lemelson-MIT Awards Finalist, First Outstanding Scientist and Technologist of Indian Origin (STIO), Westinghouse Science Talent Honors Award recipient, and was nominated for the U.S. National Medal of Technology and Innovation. In 1982, the US government recognized Ayyadurai as the inventor of email by awarding him the first Copyright for “Email” at a time when Copyright was the only way to protect software inventions. His interest in human health also began early, when as a child, he observed his grandmother, a village farmer and healer, practice Siddha, India’s oldest system of traditional medicine. This motivated his future study and research in systems biology at MIT, leading to his discovery of Systems Health®, a major breakthrough that provides an integrative framework linking eastern and western medicine. His latest invention CytoSolve®, emerging from his doctoral research at MIT, provides a revolutionary platform for modeling complex biological phenomena, to support the development multi-combination medicines without animal testing.
A major concern in the natural products industry is that there is a lack of evidence-based data to demonstrate that products are safe, efficacious and work for a particular claim, compared to the scientific data that the pharmaceutical industry is able to produce, organize and market. What has been desperately missing for the industry is a solution or technology to demonstrate how, at the molecular systems level, using evidence-based science, the products are efficacious, safe and properly dosed. For the industry’s growth and survival, there is a desperate need to move beyond “brand marketing” and anecdotal information. The revolutionary development of CytoSolve, by MIT-trained systems biologist, Dr. Shiva Ayyadurai, the man who invented email, provides the solution. CytoSolve’s ability to discover not only multi-combination therapeutics but also understand the effects of foods and supplements at the molecular systems level, enables the development of both pharmaceuticals and new food/supplement products faster, safer and more cost effectively. CytoSolve is a true game-changer for the natural products industry, providing a gateway to bring innovation and undiscovered efficacy for nutritional products to countless consumers globally.
National Chung Hsing University, Taiwan
Time : 11:30-12:00
Professional specialties of Lee-Tian Chang are research and development on herb medicine(s) and diabetes/ obesity animal models. His team developed Bidens pilosa and its active phytocompounds as an alternative anticoccidial diet additive on chickens. Two related patents and two technique transfer were approved. This study also found B. pilosa improved chicken gut microbiome. Research and development of a phytogenics to improve the health of broiler/layer and replace antibiotics on chicken feed additives is main purpose of this project.
Statement of the Problem: Coccidiosis is an economically important disease in the poultry industry. It causes an annual loss of 3 billion US dollars. Eimeria species are protozoan parasites that infect the intestinal guts and cause symptoms and even death in poultry. European union plans to ban the preventive use of anti-coccidial chemicals by 2020 because of their food safety and public health issues. Edible plants are emerging as an alternative option for coccidiosis control. However, their modes of action, efficacy and active compounds need to be elucidated prior to the commercial utilization.
Methodology & Theoretical Orientation: The bioactivity-directed fractionation and isolation (BDFI) strategy was used for identification of active compounds of BPP. Additionally, field trial study showed that BPP has less drug residue and resistance compared to the commercial drugs. We alos performed pyrosequencing of the PCR ampilcons based on the 16S rRNA genes of gut bacteria in chickens.
Findings: In the work, we first reported that the product (BPP) of B. pilosa, an edible and medicinal plant, suppress coccidiosis as evidenced by survival rate, birds’ appearance and gut pathology in chickens. Next, metagenomics studies showed that BPP modulated gut bacteria in chickens, including probiotic augmentation and harmful bacteria reduction.
Conclusion & Significance: We found that B. pilosa affected the composition of bacteria which was related with body weight gain, feed conversion ratio and gut pathology in chickens. In summary, this study suggests that B. pilosa has beneficial effects on growth performance and protozoan infection in chickens probably via improvement of gut bacteria. Currently, we are completing toxicology and drug residue study of BPP in an attempt to file and investigational animal drug application.